SciSparc Ltd: This Innovative Biotech May Have a 3.5x Upside

Meet SciSparc Ltd., the biotech disruptor with potential pipeline revenues of about $490,926,545

SciSparc Ltd: This Innovative Biotech May Have a 3.5x Upside

Cannabis buds are covered in sticky, shining dots of resin, and in this resin are hundreds of therapeutic compounds that contribute to the effects and benefits of cannabis. (2)

In those compounds lies the secret to incredible potential. Those hidden compounds the plant produces work together to create unique effects and benefits known as “the entourage effect.” (3)

They can produce synergy in the body to reduce inflammation and allow other drugs to do their job. (2)

THAT is a MASSIVE differentiator which makes SciSparc Ltd. (NASDAQ: SPRC) so unique and so compelling.

Top 5 Reasons to Get SciSparc Ltd. to Your Radar Right Now

  1. Leveraging the “entourage effect” the company has three powerhouse cannabis-based drugs in late development to help treat Tourette Syndrome (TS), Obstructive Sleep Apnea (OSA), and Autism Spectrum Disorder (ASD). (3)
  2. SciSparc Ltd. (NASDAQ: SPRC) already has a fully approved commercial product CannAmide, approved by Health Canada. (4)
  3. Early Phase 2a studies on SciSparc’s SCI 110 is showing real progress on treating obstructive sleep apnea and appears it could rapidly make it to Phase 3. SCI 110 is also proving to be effective for Tourette Syndrome, Alzheimer’s Disease, and Agitation. (3)
  4. Aegis Capital Corp. Issued a Buy Rating Looking for a 3.5x Upside Potential (1)
  5. The company also has two more therapies in the pipeline SCI-160 for Pain and SCI-210 for Autism. (3)

SciSparc Ltd.: CannAmide™ a Fully Approved Commercial Product Approved by Health Canada

CannAmide™ is recommended for use as an anti-inflammatory to help relieve chronic pain while the tablets will be marketed to pharmacies and other retail outlets across Canada. (4)

This is incredible news as until now, opioids are pretty much the only option for many people. But we all know the devastating effects opioid abuse is wreaking on the world.

Overdose deaths amongst celebrities have been going on for years. With the recent opioid epidemic this country is facing, we are seeing more and more celebrities, and people in general, die as a result of op-i-ate addiction. Some celebrities that have recently died as a result of opioid abuse/addiction include: (5)

  • Prince
  • Philip Seymour Hoffman
  • Tom Petty
  • Heath Ledger

CannAmide Provides a Safer, Non-Addictive Treatment Option

Adi Zuloff-Shani, Ph.D. the Company’s Chief Technology Officer, commented, “The onset of commercial production is a big step on the path to commercializing our first pharmaceutical drug product. CannAmide represents a significant opportunity in the chronic pain sector, where opioids remain the mainstay of treatment. Despite the increase in related addiction, overdose and death, opioids continue to generate nearly $20 billion in revenue annually. Our formulation relies on naturally occurring PEA, and therefore has no known serious side effects or drug interactions, making it what we believe to be a safe treatment option.” (4)

SciSparc Ltd.: SCI-110 is Very Close to Tapping into the $7.1 Billion Sleep Apnea Market

It is estimated that 22 million Americans suffer from sleep apnea, with 80 percent of the cases of moderate and severe obstructive sleep apnea undiagnosed. (6)

Several studies have shown an association between sleep apnea and problems like type 2 diabetes, strokes, heart attacks, and even a shortened lifespan. (7)

Currently in Phase 2a SciSparc’s SCI 110 is looking to completely disrupt the sleep apnea devices market, currently valued at USD $7.1 billion, and projected to reach USD 9.9 billion by 2026. (8)

Early Results are VERY Encouraging (3)

  • Of the 10 patients recruited into the study, nine patients have completed the study and one has dropped out of the study due to a treatment-associated adverse event (dizziness).
  • Among the remaining nine patients, 55% demonstrated significant improvement in Apnea-Hypopnea Index (AHI) values marking a reduction of around 54%.
  • Two patients reported mild side effects which were resolved when the dosages of T-H-C were reduced to 5 mg/day.
  • In general, SCI 110 therapy was well tolerated and has exhibited no serious adverse events.

The company is closer than ever to treating what could be considered an actual plague, and if anything, the most silent of killers.

SciSparc Ltd.: SCI-110 is Also Showing Tremendous Promise in Treating Tourette Syndrome, Alzheimer’s Disease, and Agitation

The global Tourette syndrome market is expanding at a rapid pace due to the consistent efforts of several organizations to increase awareness regarding the disease among patients. (9)

The major factor driving the growth of the market is the increasing cases of Tourette syndrome all across the world. As per the data of the CDC study, 1 of every 360 (0.3%) children 6-17 years of age in the US have received a diagnosis of TS, which is about 138,000 children. (9)

Tourette Syndrome: SCI-110 Showed Great Promise in their Yale University Study

According to Aegis Capital, Tourette’s treatment alone has an upside revenue potential of over $383 million in revenue.

Alzheimer’s Disease: SCI-110 Showed Great Promise in their Yale University Study

Alzheimer’s disease is a brain disorder that slowly destroys memory and thinking skills, and, eventually, the ability to carry out the simplest tasks. In most people with Alzheimer’s, symptoms first appear later in life. Estimates vary, but experts suggest that more than 6 million Americans, most of them age 65 or older. (10)

This disease is complex, and it is therefore unlikely that anyone drug or other intervention will ever successfully treat it in all people living with the disease. Still, in recent years, scientists have made tremendous progress in better understanding Alzheimer’s and in developing and testing new treatments, including several medications that are in late-stage clinical trials. (11)

As of the writing of this report, SCI-110 is in Phase 2a trials for Alzheimer’s Disease. If successful, the outlook from a revenue standpoint is incredible. We’re talking about a potential of $107 million in annual revenue.

SciSparc Ltd. (NASDAQ: SPRC): The Pipeline also Includes Potential Therapies for Pain and Autism

Autism spectrum disorder (ASD) is a developmental disability that can cause significant social, communication, and behavioral challenges. There is currently no cure for ASD. However, research shows that early intervention treatment services can improve a child’s development. (13)

In 2021, the CDC reported that approximately 1 in 44 children in the U.S. is diagnosed with an autism spectrum disorder (ASD), according to 2018 data. (12)

  • in 27 boys identified with autism
  • 1 in 116 girls identified with autism

In 2021, SciSparc entered an agreement with The Sheba Fund for Health Services and Research to perform a preclinical study for SCI-210. (1)

They also announced positive topline results in a controlled preclinical trial on neuropathic and postoperative pain for SCI-160. (1)

SciSparc Ltd. (NASDAQ: SPRC) Has Solid Financials with No Debt

The company’s current liabilities make up less than 10% of its total assets of $8.3 million. (14)

And fiscally they appear stellar with no debt on the books. (14)

According to SimplyWallStreet, the company offers a good value based on Price to Book of 1.9x vs the US Biotech Industry of 2.5x as a whole. (14)

SciSparc Ltd: This Innovative Biotech May Have a 3.5x Upside

Aegis Capital Corp. Issues a Buy Rating Looking for a 3.5x Upside Potential (1)

On January 3, 2022, Aegis Capital Corporation released a detailed report on SciSparc Ltd. (NASDAQ: SPRC). They gave a buy rating, with all the technical reasons and a full write-up. You can access the report here.


  1. Aegis Capital Corporation Report
  3. Company Investor Deck